Table 1.
Analysis of pathways significantly enriched in the list of differentially expressed genes.
| KEGG Pathway Analysis | |||
|---|---|---|---|
| Analysis Name | Gene Number | p-Value | Altered Genes |
| Pathways in cancer | 21 | 1.00 × 10−1 | CEBPA, STAT5A, CBL, CXCL8, NFKBIA, GNG12, APPL1, CBLB, CDKN1A, EP300, GNAQ, CXCR4, NCOA4, TGFA, PIK3R5, LAMC2, RARB, NOS2, CRK, CHUK, TRAF3 |
| Cytokine–cytokine receptor interaction | 18 | 3.60 × 10−3 | CSF3, IL9, CXCL8, CCL28, TNFRSF4, CCL4, IFNAR1, TNFRSF1B, TNFRSF11B, PRLR, TNFSF13B, IL10RB, CXCR4, IL4R, IL13RA1, IFNGR2, BMPR1A |
| Jak–STAT signalling pathway | 16 | 1.60 × 10−4 | CSF3, STAT5A, SOCS1, IL9, SOCS4, IL24, IFNAR1, EP300, PRLR, IL10RB, IL4R, PIK3R5, JAK3, IL13RA1, IFNGR2 |
| Regulation of actin cytoskeleton | 15 | 1.40 × 10−2 | ITGAL, SSH1, DIAPH1, SSH2, ARPC5, GNG12, PPP1CC, NCKAP1, ARPC1B, ITGB7, PIK3R5, MSN, PIP4K2A, CRK, MYLK |
| HTLV-I infection | 15 | 8.30 × 10−2 | ITGAL, TLN1, KAT2B, STAT5A, NFKBIA, MYBL2, ATM, SLA-8, CDKN1A, EP300, ETS1, PIK3R5, JAK3, NFATC3, CHUK |
| Transcriptional misregulation in cancer | 14 | 3.80 × 10−3 | CEBPA, CEBPB, KMT2A, CEBPE, LDB1, CCNT1, ELANE, CXCL8, ATM, HHEX, CDKN1A, ITGB7, GOLPH3L |
| Herpes simplex infection | 14 | 1.60 × 10−2 | CSNK2A2, CFP, EP300, HNRNPK, TAF5, EIF2S1, NFKBIA, HCFC2, PPP1CC, IFNGR2, CHUK, IFNAR1, SLA-8, TRAF3 |
| Viral carcinogenesis | 14 | 1.90 × 10−2 | LOC100156127, KAT2B, UBE3A, STAT5A, NFKBIA, PMAIP1, SLA-8, CDKN1A, HNRNPK, EP300, PIK3R5, JAK3, LOC100621389, TRAF3 |
| Insulin signalling pathway | 13 | 2.40 × 10−3 | SOCS1, CBL, ACACA, FBP1, RPS6KB1, SOCS4, PPP1CC, CBLB, PYGM, PYGL, PIK3R5, CRK, INSR |
| Chemokine signalling pathway | 13 | 2.30 × 10−2 | AMCF-II, CXCR4, CXCL2, CXCL8, NFKBIA, PIK3R5, FOXO3, GNG12, JAK3, CCL4, CCL28, CRK, CHUK |
| Epstein–Barr virus infection | 12 | 7.90 × 10−2 | CSNK2A2, ITGAL, CDKN1A, EP300, IL10RB, NFKBIA, PIK3R5, JAK3, TNFAIP3, CHUK, SLA-8, TRAF3 |
| Measles | 11 | 1.80 × 10−2 | CSNK2A2, EIF2S1, STAT5A, NFKBIA, PIK3R5, JAK3, MSN, TNFAIP3, IFNGR2, CHUK, IFNAR1 |
| Ubiquitin-mediated proteolysis | 11 | 2.00 × 10−2 | CUL5, CBLB, UBE3A, UBR5, WWP1, SOCS1, CBL, RHOBTB1, KEAP1, LOC780419, TRIP12 |
| Prolactin signalling pathway | 10 | 2.90 × 10−4 | CGA, PRLR, STAT5A, SOCS1, IRF1, SOCS4, PIK3R5, FOXO3, LHB, CSN2 |
| Salmonella infection | 10 | 1.50 × 10−3 | ARPC1B, CXCL2, PKN2, CXCL8, ARPC5, NOS2, DYNC1H1, CASP1, CCL4, IFNGR2 |
| NF-kappa B signalling pathway | 10 | 3.10 × 10−3 | CSNK2A2, TNFSF13B, LY96, CXCL8, NFKBIA, TNFAIP3, CCL4, ATM, CHUK, TRAF3 |
| TNF signalling pathway | 10 | 1.20 × 10−2 | LOC100736836, TNFRSF1B, CEBPB, CXCL2, NFKBIA, PIK3R5, TNFAIP3, CHUK, TRAF3 |
| Hepatitis C | 10 | 3.30 × 10−2 | CDKN1A, EIF2S1, IRF1, CXCL8, NFKBIA, PIK3R5, CHUK, IFNAR1, PPP2R2A, TRAF3 |
| Osteoclast differentiation | 10 | 4.30 × 10−2 | CYLD, TNFRSF11B, CTSK, SOCS1, NFKBIA, PIK3R5, IFNGR2, SIRPA, CHUK, IFNAR1 |
| ErbB signalling pathway | 9 | 7.20 × 10−3 | CBLB, CDKN1A, STAT5A, CBL, TGFA, PIK3R5, RPS6KB1, ABL2, CRK |
| Toll-like receptor signalling pathway | 9 | 2.10 × 10−2 | CTSK, LY96, CXCL8, NFKBIA, PIK3R5, CCL4, CHUK, IFNAR1, TRAF3 |
| Chagas disease (American trypanosomiasis) | 9 | 2.90 × 10−2 | GNAQ, CD247, CXCL8, NFKBIA, PIK3R5, NOS2, IFNGR2, CHUK, PPP2R2A |
| Insulin resistance | 9 | 3.80 × 10−2 | RPS6KA3, PYGM, PYGL, NFKBIA, PIK3R5, RPS6KB1, PPP1CC, SLC27A2, INSR |
| Toxoplasmosis | 9 | 4.10 × 10−2 | LY96, IL10RB, SOCS1, NFKBIA, LAMC2, PIK3R5, NOS2, IFNGR2, CHUK |
| AMPK signalling pathway | 9 | 4.70 × 10−2 | EEF2K, ACACA, FBP1, RAB14, PIK3R5, RPS6KB1, FOXO3, INSR, PPP2R2A |
| Chronic myeloid leukemia | 8 | 6.50 × 10−3 | CBLB, CDKN1A, STAT5A, CBL, NFKBIA, PIK3R5, CRK, CHUK |
| Ribosome biogenesis in eukaryotes | 8 | 1.80 × 10−2 | CSNK2A2, RN18S, MPHOSPH10, NOP58, WDR3, NOP56, BMS1, GNL3 |
| HIF-1 signalling pathway | 8 | 5.20 × 10−2 | PDK1, CDKN1A, EP300, PIK3R5, RPS6KB1, NOS2, IFNGR2, INSR |
| Bacterial invasion of epithelial cells | 7 | 3.40 × 10−2 | ARPC1B, CBLB, CBL, PIK3R5, ARPC5, CRK, ARHGAP10 |
| Peroxisome | 7 | 4.80 × 10−2 | ACSL1, NUDT12, NOS2, SLC27A2, ACSL3, CROT, SOD2 |
| Small cell lung cancer | 7 | 5.90 × 10−2 | NFKBIA, LAMC2, PIK3R5, NOS2, RARB, CHUK, TRAF3 |
| Phosphatidylinositol signalling system | 7 | 9.40 × 10−2 | MTMR14, PI4KA, PIK3R5, DGKH, INPP4A, PIP4K2A, INPP5B |
| Systemic lupus erythematosus | 7 | 9.80 × 10−2 | LOC100156127, LOC100157763, LOC100158121, ELANE, LOC100154071, LOC100153329, LOC100621389 |
| Pertussis | 6 | 7.50 × 10−2 | AMCF-II, LY96, IRF1, CXCL8, NOS2, CASP1 |
| NOD-like receptor signalling pathway | 5 | 5.10 × 10−2 | CXCL8, NFKBIA, TNFAIP3, CASP1, CHUK |
| Ovarian steroidogenesis | 5 | 5.40 × 10−2 | CGA, PLA2G4A, HSD3B1, LHB, INSR |
| Malaria | 5 | 5.80 × 10−2 | CSF3, ITGAL, SELP, CXCL8 |
| Acute myeloid leukemia | 5 | 6.70 × 10−2 | CEBPA, STAT5A, PIK3R5, RPS6KB1, CHUK |
| Pentose phosphate pathway | 4 | 1.10 × 10−2 | FBP1, TKT, RPIA, PRPS2 |
| Intestinal immune network for IgA production | 4 | 9.50 × 10−2 | TNFSF13B, CXCR4, ITGB7, CCL28 |
| Fatty acid biosynthesis | 3 | 1.40 × 10−2 | ACSL1, ACACA, ACSL3 |
| Glycosaminoglycan biosynthesis-chondroitin sulphate/dermatan sulphate | 3 | 5.10 × 10−2 | CSGALNACT2, CHST3, CHSY1 |
| Nicotinate and nicotinamide metabolism | 3 | 9.40 × 10−2 | ENPP1, NUDT12, NMRK1 |
| Dorso-ventral axis formation | 3 | 9.40 × 10−2 | CPEB2, ETS1, CPEB4 |